Dae Gon Ha
Stock Analyst at Stifel
(2.66)
# 2,082
Out of 4,711 analysts
48
Total ratings
30.77%
Success rate
1.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $1.31 | +129.01% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $45.18 | +63.79% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $4.35 | -31.03% | 4 | Sep 12, 2024 | |
| INZY Inozyme Pharma | Initiates: Buy | $16 | $2.99 | +435.12% | 1 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $12.18 | +425.45% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $164.83 | +33.47% | 4 | Sep 11, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $48 → $66 | $41.51 | +59.00% | 3 | Jun 20, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $44.22 | +187.20% | 2 | May 31, 2024 | |
| ABEO Abeona Therapeutics | Initiates: Buy | $21 | $5.70 | +268.42% | 1 | May 30, 2024 | |
| VERV Verve Therapeutics | Maintains: Buy | $56 → $40 | $5.74 | +596.86% | 3 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $11.56 | +315.22% | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.90 | +520.69% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $0.61 | +1,051.32% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $56.12 | -55.45% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $9.80 | +63.27% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $10.57 | +2,597.59% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.63 | +660.46% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $13.00 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $33.21 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $7.57 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.24 | +435.71% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $3.19 | +15,260.50% | 2 | Oct 23, 2017 |
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $1.31
Upside: +129.01%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $45.18
Upside: +63.79%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $4.35
Upside: -31.03%
Inozyme Pharma
Sep 12, 2024
Initiates: Buy
Price Target: $16
Current: $2.99
Upside: +435.12%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $12.18
Upside: +425.45%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $164.83
Upside: +33.47%
Mirum Pharmaceuticals
Jun 20, 2024
Maintains: Buy
Price Target: $48 → $66
Current: $41.51
Upside: +59.00%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $44.22
Upside: +187.20%
Abeona Therapeutics
May 30, 2024
Initiates: Buy
Price Target: $21
Current: $5.70
Upside: +268.42%
Verve Therapeutics
Apr 3, 2024
Maintains: Buy
Price Target: $56 → $40
Current: $5.74
Upside: +596.86%
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $11.56
Upside: +315.22%
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $2.90
Upside: +520.69%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $0.61
Upside: +1,051.32%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $56.12
Upside: -55.45%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $9.80
Upside: +63.27%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $10.57
Upside: +2,597.59%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $2.63
Upside: +660.46%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $13.00
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $33.21
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $7.57
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $2.24
Upside: +435.71%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $3.19
Upside: +15,260.50%